![](/img/cover-not-exists.png)
2365 Nanoliposomal irinotecan (MM-398, nal-IRI) population pharmacokinetics (PK) and its association with efficacy and safety in patients with solid tumors based on the phase 3 study NAPOLI-1 and five phase 1 and 2 studies
Ma, W.W., Chung, I., Lang, I., Csõszi, T., Wenczl, M.W., Cubillo, A., Chen, J., Wong, M., Park, J.O., Kim, J.S., Rau, K.M., Melichar, B., Gallego, J., Smakal, M., Kim, J., Belanger, B., Bayever, E., AVolume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)31281-3
Date:
September, 2015
File:
PDF, 60 KB
english, 2015